MEDICURE INC (MPH.CA) Stock Price, Forecast & Analysis

TSX-V:MPH • CA58469E4085

1.12 CAD
-0.02 (-1.75%)
Last: Feb 12, 2026, 07:00 PM

MPH.CA Key Statistics, Chart & Performance

Key Statistics
Market Cap11.69M
Revenue(TTM)26.21M
Net Income(TTM)-3.43M
Shares10.44M
Float7.63M
52 Week High1.43
52 Week Low0.63
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.33
PEN/A
Fwd PEN/A
Earnings (Next)04-27
IPO1999-03-30
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
MPH.CA short term performance overview.The bars show the price performance of MPH.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 -2 -4 -6 -8 -10

MPH.CA long term performance overview.The bars show the price performance of MPH.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 2 -2 4 -4

The current stock price of MPH.CA is 1.12 CAD. In the past month the price decreased by -7.44%. In the past year, price increased by 4.67%.

MEDICURE INC / MPH Daily stock chart

MPH.CA Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to MPH.CA. When comparing the yearly performance of all stocks, MPH.CA is a bad performer in the overall market: 61.92% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
MPH.CA Full Technical Analysis Report

MPH.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to MPH.CA. The financial health of MPH.CA is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MPH.CA Full Fundamental Analysis Report

MPH.CA Financial Highlights

Over the last trailing twelve months MPH.CA reported a non-GAAP Earnings per Share(EPS) of -0.33. The EPS decreased by -68.69% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -12.83%
ROE -19.81%
Debt/Equity 0.03
Chartmill High Growth Momentum
EPS Q2Q%-279.68%
Sales Q2Q%56.6%
EPS 1Y (TTM)-68.69%
Revenue 1Y (TTM)24.3%
MPH.CA financials

MPH.CA Forecast & Estimates


Analysts
Analysts40
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
MPH.CA Analyst EstimatesMPH.CA Analyst Ratings

MPH.CA Ownership

Ownership
Inst Owners23.1%
Ins Owners26.42%
Short Float %N/A
Short RatioN/A
MPH.CA Ownership

MPH.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
EPRX EUPRAXIA PHARMACEUTICALS INC N/A596.271M
EDT SPECTRAL MEDICAL INC N/A380.328M
HBP HELIX BIOPHARMA CORP N/A141.303M
MDNA MEDICENNA THERAPEUTICS CORP N/A69.23M
COV COVALON TECHNOLOGIES LTD13.1144.744M
BCT BRIACELL THERAPEUTICS CORP N/A39.875M
MBX MICROBIX BIOSYSTEMS INC5.4530.481M
RVX RESVERLOGIX CORP N/A27.318M
HEM HEMOSTEMIX INC N/A17.573M

About MPH.CA

Company Profile

MPH logo image Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. The company is headquartered in Winnipeg, Manitoba and currently employs 23 full-time employees. Its primary focus is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through its United States subsidiary, Medicure Pharma Inc. The company operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medications for all Americans, together with customer service and free home delivery. The company operates Gateway Medical Pharmacy, located in Portland, Oregon in a medical office building near transportation lines and multiple healthcare clinics and centers. The company develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, and compositions containing P5P Analogues.

Company Info

MEDICURE INC

1250 Waverley Street

Winnipeg MANITOBA R3T 6C6 CA

CEO: Albert D. Friesen

Employees: 38

MPH Company Website

MPH Investor Relations

Phone: 12044877412

MEDICURE INC / MPH.CA FAQ

Can you describe the business of MEDICURE INC?

Medicure, Inc. is a pharmaceutical company, which engages in the research, clinical development, and commercialization of cardiovascular therapeutics. The company is headquartered in Winnipeg, Manitoba and currently employs 23 full-time employees. Its primary focus is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through its United States subsidiary, Medicure Pharma Inc. The company operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medications for all Americans, together with customer service and free home delivery. The company operates Gateway Medical Pharmacy, located in Portland, Oregon in a medical office building near transportation lines and multiple healthcare clinics and centers. The company develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, and compositions containing P5P Analogues.


What is the current price of MPH stock?

The current stock price of MPH.CA is 1.12 CAD. The price decreased by -1.75% in the last trading session.


Does MPH stock pay dividends?

MPH.CA does not pay a dividend.


What is the ChartMill rating of MEDICURE INC stock?

MPH.CA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


How is the valuation of MEDICURE INC (MPH.CA) based on its PE ratio?

MEDICURE INC (MPH.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.33).


What is the ownership structure of MEDICURE INC (MPH.CA)?

You can find the ownership structure of MEDICURE INC (MPH.CA) on the Ownership tab.